

**S5 Table.** Characteristics of patients according to the use of durvalumab in patients with PD-L1–positive tumors

	Patients with PD-L1–positive tumors (n=102)		p-value
	CCRT alone (n=40)	CCRT+Durvalumab (n=62)	
Age (yr)	68 (45-85)	63 (36-76)	0.043
Sex			
Male	33 (82.5)	50 (80.6)	> 0.99
Female	7 (17.5)	12 (19.4)	
ECOG PS			
0-1	35 (87.5)	58 (93.5)	0.488
2-3	5 (12.5)	4 (6.5)	
Underlying lung disease			
No	31 (77.5)	57 (91.9)	0.076
Yes	9 (22.5)	5 (8.1)	
Smoking status			
Never-smoker	7 (17.5)	16 (25.8)	0.461
(Ex-)Smoker	33 (82.5)	46 (74.2)	
PFT			
FVC (%)	81.0±12.7	79.8±12.0	0.634
FEV <sub>1</sub> (L)	2.2±0.6	2.3±0.6	0.363
FEV <sub>1</sub> (%)	73.1±16.7	74.0±15.7	0.784
DLCO (%)	68.0±15.6	73.9±15.5	0.110
Tumor histology			
Squamous cell carcinoma	21 (52.5)	25 (40.3)	0.382
Adenocarcinoma	17 (42.5)	35 (56.5)	
Others	2 (5.0)	2 (3.2)	
Clinical T category			
cT1-2	24 (60.0)	29 (46.8)	0.270
cT3-4	16 (40.0)	33 (53.2)	
Clinical N category			
cN0-1	15 (37.5)	8 (12.9)	0.008
cN2-3	25 (62.5)	54 (87.1)	
Stage			
IIB	11 (27.5)	4 (6.5)	0.006
IIIA	10 (25.0)	12 (19.4)	
IIIB	13 (32.5)	39 (62.9)	
IIIC	6 (15.0)	7 (11.3)	
EGFR mutation			
Negative	16 (40.0)	21 (33.9)	0.208
Positive	3 (7.5)	12 (19.4)	
Not checkable	21 (52.5)	29 (46.8)	
Total RT dose (Gy)	60.0 (50.0-68.0)	60.0 (56.0-70.4)	0.796
Fraction size (Gy/fx)	2.0 (1.8-2.2)	2.0 (2.0-2.2)	0.522
Induction chemotherapy before CCRT			
No	35 (87.5)	62 (100.0)	0.017
Yes	5 (12.5)	0	
Chemotherapy agent			

Paclitaxel/Cisplatin	31 (77.5)	53 (85.5)	0.328
Paclitaxel/ Carboplatin	5 (12.5)	4 (6.5)	
Etoposide/Cisplatin	2 (5.0)	5 (8.1)	
Etoposide/Carboplatin	1 (2.5)	0	
Cisplatin/Pemetrexed	1 (2.5)	0	

Values are presented as median (range), number (%), or mean±SD. Because of rounding off, not all of the percentages total 100. CCRT, concurrent chemoradiotherapy; DLCO, diffusing capacity of the lung for CO; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; FEV<sub>1</sub>, forced expiratory volume in one second; FVC, forced vital capacity; PD-L1, programmed cell death ligand 1; PFT, pulmonary function test; RT, radiotherapy; SD, standard deviation.